Thermo Fisher Scientific Certifies Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System to Meet IVDR Requirements
12.9.2022 09:30:00 EEST | Business Wire | Press release
Thermo Fisher Scientific has certified the Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System* to meet new In Vitro Medical Devices Regulation (IVDR) requirements. The updated system now includes new, complementary Applied Biosystems Diomni Software ecosystem to empower clinical labs and test developers to leverage flexible PCR testing onsite.
Designed for maximum productivity and fast ramp-up, the QuantStudio 7 Pro Dx Real-Time PCR System enables users to transition from development to validation on a single system. The expandable, automated platform comes with interchangeable 96-well and 384-well blocks and also includes remote desktop and touchscreen controls, facial authentication, voice command and smart tech support to increase user productivity.
“We have continued to support our customers throughout the transition to IVDR, first by introducing the updated Applied Biosystems QuantStudio 5 Dx Real-Time PCR System earlier this year and now with the launch of the IVDR-compliant QuantStudio 7 Pro Dx Real-Time PCR System and new complementary Diomni Software ecosystem,” said Fernando Beils, vice president and general manager of qPCR instruments at Thermo Fisher Scientific. “As test developers and laboratories expand their assay menus and IVD testing capabilities, we are committed to continue providing innovative solutions to meet their evolving needs.”
Whether performing a routine test or developing a new assay, the integrated, IVDR-compliant Applied Biosystems Diomni Software ecosystem is designed to streamline the entire workflow with a plug-and-play design and simplified set-up to enhance efficiency and minimize user error. The centralized set-up allows connection to multiple real-time PCR instruments and secure data sharing across a user network.
“The ability to import plate set-up files from external software and export result sets in a customizable structure made it easy to integrate the QuantStudio 7 Pro Dx Real-Time PCR System with our laboratory information management software,” said Dr. Gustav Quade, laboratory medicine and technical development specialist at the Quade Laboratory in Germany. “The new Diomni Software makes it easy to work collaboratively and we can set up runs, manage past runs and documentation, and interpret fluorescent curves remotely and efficiently without the need to install special software.”
The QuantStudio 7 Pro Dx Real-Time PCR System is available in all regions that recognize CE-IVD certification and is also listed with the U.S. Food and Drug Administration (FDA) as a class II medical device.
For more information, please visit www.thermofisher.com/quantstudio7prodx.
*The QuantStudio 7 Pro Dx Real-Time PCR System is For In Vitro Diagnostic Use.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
For more information, please visit www.thermofisher.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220911005026/en/
Contact information
Media Contact Information:
Mauricio Minotta
Phone: 760-805-5266
Email: mauricio.minotta@thermofisher.com
Jennifer Heady
Phone: 413-237-5141
Email: jheady@greenough.biz
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xylem Announces Segment Leadership Appointments30.6.2026 14:30:00 EEST | Press release
Xylem Inc. (NYSE: XYL), a leading global water solutions company, today announced two executive leadership appointments, effective July 1, both reporting to President and Chief Executive Officer Matthew Pine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630087773/en/ Meredith Emmerich has been appointed EVP and President, Measurement and Control Solutions at Xylem. Meredith Emmerich has been appointed EVP and President, Measurement and Control Solutions. Most recently, she served as EVP and President, Applied Water at Xylem. Emmerich joined Xylem in 2024 from Carrier Global Corporation (NYSE: CARR), where she was Vice President of Global Enterprise Solutions and held several senior leadership roles, including leading the Americas Commercial HVAC business and the Global Residential, Light Commercial, and VRF HVAC portfolio. Emmerich succeeds Mike McGann, who will serve as senior advisor to ensure a smooth and orderly tra
Strike Europe Secures Full MiCA Authorization, Unlocking Bitcoin Services Across All 27 EU Member States30.6.2026 14:29:00 EEST | Press release
Strike, a leading Bitcoin financial services company, today announced that its European entity, Zap (Strike) Europe Limited, has been authorized as a crypto-asset service provider by the Malta Financial Services Authority (MFSA) under the EU's Markets in Crypto-Assets Regulation (MiCA) and the Malta Markets in Crypto Assets Act (Cap. 647, laws of Malta) to provide crypto-asset services. The license enables millions of Europeans across all 27 EU member states to access Strike's suite of Bitcoin financial services under a single regulatory framework, replacing the patchwork of national regimes that previously governed the market. Strike has served eligible European customers since April 2024. The MFSA authorization makes that presence permanent and EU-wide, and positions the company among a small group of firms to complete the MiCA process to date. "Europe deserves a Bitcoin-only company focused on doing one thing well, not a multi-asset platform where Bitcoin is an afterthought," said J
OpZira, Inc. Welcomes Scott Thielman, PhD, as Vice President of Product Development30.6.2026 14:17:00 EEST | Press release
OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced that Scott Thielman, PhD, PE, has joined the company as Vice President of Product Development, effective May 1, 2026. Dr. Thielman brings a unique connection to OpZira’s origins. As Chief Technology Officer of Product Creation Studio, he directed the product development of LumiThera’s Valeda® Light Delivery System - the breakthrough photobiomodulation therapy for dry age-related macular degeneration whose acquisition by Alcon led to the creation of OpZira. His involvement with Valeda gives him firsthand knowledge of the science, clinical vision, and engineering decisions that shaped the technology platform from which OpZira was born. For more than 25 years, Dr. Thielman has directed the development of dozens of FDA-cleared medical devices across ophthalmology, neurostimulation, dermatology, urology, and surgical instrumentation, with partners including Olympus
L&T Technology Services Launches Ainfonix ™ 4.0 to Unlock Engineering Intelligence Across Process Industries30.6.2026 13:45:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced the launch of Ainfonix™ 4.0, a next-generation Engineering Intelligence platform for process industries. Unveiled at EI Live, LTTS’ flagship event that brings together analysts, industry leaders and engineering experts, Ainfonix™ 4.0 marks an important step in the company’s Enterprise AI and Engineering Intelligence strategy. As industrial enterprises accelerate AI adoption, decades of engineering knowledge remain trapped in fragmented drawings, specifications and technical records across disparate systems. Without trusted and accessible engineering data, organizations struggle to realize the full value of AI, automation and digital transformation initiatives. Ainfonix™ 4.0, developed in LTTS’ Sustainability segment, addresses this challenge by transforming engineering artifacts and multi-modal data into structured, asset-linked information
Klick Health Acquires Oxford PharmaGenesis, Bringing Together Unsurpassed Scientific-to-Commercial Capabilities for Life Sciences Clients30.6.2026 13:03:00 EEST | Press release
Focused on taking life sciences companies into the future, Klick Health today announced its acquisition of Oxford PharmaGenesis, the market-leading HealthScience communications consultancy renowned for its scientific and medical expertise, as well as value and market access consulting throughout Europe, Asia-Pacific, and North America. Today’s news brings together two of the leading independent agencies in life sciences. With Oxford PharmaGenesis’ expertise across medical affairs and market access, and Klick's strength in commercial strategy, medical, creative, digital, analytics, and experience design, they can deliver an unparalleled scientific-to-commercial experience. “We are beyond proud to join forces with Chris, Richard, and the entire team at Oxford PharmaGenesis as we focus on helping life sciences clients think holistically about how evidence, medical strategy, access considerations, and stakeholder engagement connect across the lifecycle with a scientific-to-commercial offer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
